Action NTRA NATERA, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Natera, Inc.

Actions

NTRA

US6323071042

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 07/06/2024 		Varia. 5j. Varia. 1 janv.
111,2 USD +1,80 % Graphique intraday de Natera, Inc. +4,37 % +77,51 %
03/06 NATERA, INC. : Jefferies & Co. à l'achat ZM
30/05 Transcript : Natera, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-30-2024 10:40 AM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
U.S. FDA advisers back approval for Guardant's cancer test
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
Natera Insider Sold Shares Worth $3,137,567, According to a Recent SEC Filing
Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024
Top Premarket Gainers
Natera Q1 Loss Narrows, Revenue Rises; Full-Year Revenue Guidance Raised -- Shares Jump After Hours
Natera: Q1 Earnings Snapshot
Natera : Q1 2024 Earnings Presentation
Natera, Inc. Provides Earnings Guidance for the Year 2024
Earnings Flash (NTRA) NATERA Reports Q1 Revenue $367.7M, vs. Street Est of $315.3M
Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Natera Reports First Quarter 2024 Financial Results
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera in Breast Cancer
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
Natera, Inc. Announces a New Publication in JCO Precision Oncology Reporting on the Ability of its Personalised and Tumor-Informed Molecular Residual Disease Test, Signatera
Natera to Report its First Quarter 2024 Results on May 9
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NTRA
  4. Actualités Natera, Inc.
  5. Autres langues